Tempus AI, Inc. (NASDAQ:TEM) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC increased its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 0.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 133,171 shares of the company’s stock after purchasing an additional 539 shares during the quarter. Geode Capital Management LLC’s holdings in Tempus AI were worth $7,537,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TEM. First Horizon Advisors Inc. purchased a new stake in Tempus AI during the 3rd quarter worth approximately $30,000. Sandia Investment Management LP acquired a new stake in shares of Tempus AI in the second quarter worth approximately $136,000. Vestor Capital LLC acquired a new position in Tempus AI in the 3rd quarter valued at $153,000. Stifel Financial Corp acquired a new position in Tempus AI in the 3rd quarter valued at $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in Tempus AI in the 3rd quarter valued at $258,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director David R. Epstein sold 620 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the transaction, the director now owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Ryan Fukushima sold 120,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total value of $5,101,200.00. Following the completion of the sale, the chief operating officer now directly owns 1,007,207 shares in the company, valued at approximately $42,816,369.57. The trade was a 10.65 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 845,041 shares of company stock valued at $35,125,473.

Analysts Set New Price Targets

TEM has been the subject of a number of recent research reports. Wolfe Research began coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Bank of America boosted their target price on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Loop Capital increased their price target on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Finally, Guggenheim began coverage on Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Tempus AI Trading Up 1.5 %

NASDAQ:TEM opened at $34.25 on Friday. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $79.49. The stock’s fifty day moving average is $49.04 and its two-hundred day moving average is $46.62. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.